Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $290.28M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.90M
Average 0.38M
EVMN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Evommune, Inc.NYSE: EVMN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows 20.6% year over year
Q1 FY2026 research & development of $17.32M rose 20.6% year over year. Sequentially, it fell 15.1% from the prior quarter.
Context
- Research & development amounted to 569.6% of revenue in FY2025, down 348.2 pp from a year earlier.
- Research & development increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 74.04M USD
- Year-over-year change
- +15.3%
- 2-year CAGR
- +52.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.04M | +15.3% |
| FY2024 | 2024-12-31 | 64.24M | +100.8% |
| FY2023 | 2023-12-31 | 32M | — |
Research & Development vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 research & development of $77M is the 4th highest of the 10 companies compared; the peer median is $47.7M.
- Research & development amounts to 770.0% of revenue for EVMN, versus a peer median of 82.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.51B | +1655.5% | -13.1% | 942.7% | |
| LTM Mar 2026 | $234.61M | +45.4% | +64.5% | 3080.9% | |
| LTM Mar 2026 | $124.78M | -12.3% | -5.5% | 82.6% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $77M | — | — | 770.0% |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $71.8M | +27.7% | +16.5% | — |
| LTM Mar 2026 | $47.7M | -0.5% | -13.2% | 61.1% | |
| LTM Mar 2026 | $44.75M | -15.8% | -0.4% | 154.8% | |
| LTM Jun 2026 | $41.35M | -38.1% | +31.0% | 14.2% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $38.72M | -52.9% | +21.2% | — |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $0 | — | — | 0.0% |
| Peer median (excluding EVMN) | $47.7M | -6.4% | +8.0% | 82.6% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$7.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.